Mutlu Demiray
Overview
Explore the profile of Mutlu Demiray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tokat U, Adibi A, Aydin E, Bilgic S, Ozgu E, Tutar O, et al.
Front Oncol
. 2025 Feb;
14:1484750.
PMID: 39931207
Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy. Although this...
2.
Ozgu E, Tokat U, Adibi A, Bilgic S, Aydin E, Tutar O, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400652.
PMID: 39913887
No abstract available.
3.
Tokat U, Bilgic S, Aydin E, Adibi A, Ozgu E, Tutar O, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241297101.
PMID: 39539943
Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR/HER2...
4.
Ozgu E, Kaplan B, Sivakumar S, Sokol E, Aydin E, Tokat U, et al.
BJC Rep
. 2024 Nov;
2(1):77.
PMID: 39516363
Background: Kinase-impaired class III BRAF mutations have recently received attention as a possible prognostic factor and therapeutic target. Class III BRAF variants differ from class I and class II mutations...
5.
Tokat U, Adibi A, Aydin E, Ozgu E, Bilgic S, Tutar O, et al.
Curr Oncol
. 2024 Oct;
31(10):5838-5849.
PMID: 39451738
There is currently no effective treatment strategy for recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Furthermore, recent single-agent and combination immunotherapy trials have failed in unselected ACC cohorts, unlike non-ACC salivary...
6.
Aydin E, Tokat U, Adibi A, Ozgu E, Bilgic S, Demiray M
Front Oncol
. 2024 Jul;
14:1405170.
PMID: 39011472
Background: Metastatic colon adenocarcinoma presents significant challenges in treatment, particularly when resistant to standard therapies. Precision oncology, guided by multidisciplinary tumor boards (MTBs), offers a promising way for individualized therapeutic...
7.
Adibi A, Tokat U, Ozgu E, Mamyrov N, Aydin E, Bilgic S, et al.
Oral Oncol
. 2024 May;
154:106859.
PMID: 38781626
Cancer patients living with HIV (CPLWH) may experience increased mortality risk. Furthermore, they have been historically excluded from clinical trials due to safety concerns. Our patient with squamous cell carcinoma...
8.
Angel M, Demiray M, Disel U, Passos J
Oncologist
. 2024 May;
29(7):554-559.
PMID: 38761380
Genomic profiling and other new technologies have increased the volume and complexity of information available for guiding clinical decision-making in precision oncology. Consequently, there is a need for multidisciplinary expert...
9.
Aydin E, Tokat U, Ozgu E, Adibi A, Tutar O, Kurzrock R, et al.
Ther Adv Med Oncol
. 2024 Apr;
16:17588359241247023.
PMID: 38645422
This paper presents a patient with a novel Ig-like-III domain fibroblast growth factor receptor (FGFR2) alteration (W290_P307>C) along with CDKN2A/B alterations and a cadherin 1 (CDH1) alteration. Initial responsiveness to...
10.
Ozgu E, Aydin E, Adibi A, Tokat U, Tutar O, Hu J, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300299.
PMID: 38127827
No abstract available.